Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. is a development-stage life sciences company focused on creating a platform technology to quantify and unlock the complexity of the human proteome. Its mission is to revolutionize biomedicine by democratizing access to the proteome, thereby enabling fundamental advancements across human health and medicine, and ultimately impacting global health. The company's corporate headquarters are located in Seattle, Washington, with additional research and development facilities in San Carlos and San Diego, California.

Nautilus Biotechnology's key offering is the Nautilus Voyager™ Platform, an integrated solution that includes instruments, reagents, consumables, and software for proteome analysis. This platform utilizes a proprietary Iterative Mapping technology to perform single-molecule interrogation of intact proteins on hyper-dense nanoarrays. By employing multi-affinity probes, computational decoding, and cloud-based analysis, the system aims to provide broad proteome coverage with high sensitivity and deliver reproducible, quantifiable insights into protein and proteoform identities.

Led by co-founder and CEO Sujal Patel, Nautilus Biotechnology is actively progressing towards the commercialization of its technology. The company launched an Iterative Mapping Early Access Program in January 2026, with Baylor College of Medicine becoming its first customer for a National Institutes of Health-funded cancer study. Additionally, Nautilus has established research collaborations, including one with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation for Parkinson's Research, to advance single-molecule proteomics in disease studies. The commercial launch of the Voyager platform is anticipated in late 2026.